Research Analysts’ Weekly Ratings Updates for Ovid Therapeutics (OVID)

Several analysts have recently updated their ratings and price targets for Ovid Therapeutics (NASDAQ: OVID):

• 11/24/2025 – Ovid Therapeutics had its price target raised by analysts at HC Wainwright from $1.50 to $2.00. They now have a “buy” rating on the stock.
• 11/17/2025 – Ovid Therapeutics was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 11/17/2025 – Ovid Therapeutics is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $5.00 price target on the stock.
• 11/15/2025 – Ovid Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 10/10/2025 – Ovid Therapeutics had its “buy” rating reaffirmed by analysts at B. Riley.
• 10/9/2025 – Ovid Therapeutics is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $7.00 price target on the stock.
• 10/8/2025 – Ovid Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.